Now showing items 1-1 of 1
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
Anti-angiogenic therapy in glioblastoma (GBM) has unfortunately not led to the anticipated improvement in patient prognosis. We here describe how human GBM adapts to bevacizumab treatment at the metabolic level. By performing ...